CNTF

Executive Summary

Phase II trial of Regeneron's ciliary neurotrophic factor in over 50 ALS patients did not show statistically significant difference from placebo at doses ranging from .5 mcg/kg to 30 mcg/kg subcutaneous injections three times a week, Regeneron reports in secondary offering prospectus. "Comparisons of rates of deterioration in muscle strength and pulmonary function between patients treated with 30 mcg/kg of CNTF and placebo ranged in significance level between p = .08 and p = .20 and were of the magnitude anticipated on the basis of studies in animal models of motor neuron degeneration, Regeneron said. Anti-CNTF antibodies were seen in all patients dosed at 3 mcg/kg or greater. Based on results of the trial, the company is conducting a 700-patient Phase III study of CNTF ("The Pink Sheet" April 12, T&G-12).